Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038685 | 1.00 | HPGD (0.46) | HPGDALDH1A1L3MBTL1MAPK10TP53 | |
| SCHEMBL1492015 | 1.00 | HPGD (0.46) | HPGDALDH1A1L3MBTL1MAPK10TP53 | |
| SCHEMBL14517569 | 0.79 | L3MBTL1 (0.38) | HPGDALDH1A1L3MBTL1MAPK10TP53 | |
| SCHEMBL5239138 | 0.77 | HPGD (0.39) | HPGDALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL5239145 | 0.77 | HPGD (0.39) | HPGDALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL5239135 | 0.77 | HPGD (0.39) | HPGDALDH1A1L3MBTL1TSHRMAPT | |
| SCHEMBL12588737 | 0.75 | — | — | |
| SCHEMBL8537626 | 0.73 | — | — | |
| SCHEMBL8402032 | 0.73 | — | — | |
| SCHEMBL7180210 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060488-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-13 | — | — | WO | disclosed |
| EP-2470538-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989464-B2 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1931683-B1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1966220-B1 | MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS | SCHERING CORP (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7767815-B2 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| EP-1765829-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007032854-A1 | FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007024593-A1 | FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | SCHERING CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | SCHERING CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006002051-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072864-A1 | Fused tricyclic mGIuR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | HPGD 1841/4885ALDH1A1 1119/4885L3MBTL1 1463/4885 |
| US-20070072863-A1 | Fused tricyclic mGluR1 antagonists as therapeutic agents | GRM1, GRM3, GRIN1 | HPGD 1644/4885ALDH1A1 1121/4885L3MBTL1 1976/4885 |
| US-20060167029-A1 | mGluR1 Antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | HPGD 1200/4885ALDH1A1 1026/4885L3MBTL1 2539/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HPGD 1629/4885ALDH1A1 1048/4885L3MBTL1 1649/4885 |
| US-20060009477-A1 | mGluR1 antagonists as therapeutic agents | GRM1, GRM4, GRIA1 | HPGD 1207/4885ALDH1A1 966/4885L3MBTL1 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.